PRTC News and Press, PureTech Health plc From 03/18/21

PureTech Health (PRTC) announces that Stephen Muniz, Esq., will retire from his role as Chief Operating Officer and Corporate Secretary and will step down from the Board Of Directors, effective May 17, 2021.Bharatt Chowrira, PhD, JD, PureTech’s President and Chief of Business and Strat...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announces that Stephen Muniz, Esq., will ret...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its annual report and financial results on Thursday, April 15, 2021 at 2:00 AM EDT / 7:00 AM BST. The report will include the Company’s financial results for the year ended December 3...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that George Farmer, Ph.D., its Chi...

PureTech Health plc (NASDAQ: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that it...

Vedanta Biosciences , a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured from clonal cell banks, today announced that members of its executive team will present and host one-on-one meeting...

Publication demonstrates the ability to directly target gut lymphatics with an orally dosed small molecule immunomodulator First product candidate from Glyph platform, LYT-300 (oral allopregnanolone), expected to enter clinical trial by the end of 2021 PureTech Healt...

KarXT demonstrated statistically significant and clinically meaningful improvements in primary and key secondary efficacy measures compared with placebo Incidences of somnolence, weight gain and extrapyramidal symptoms were similar in KarXT and placebo treatment groups ...

PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that Bharatt Chowrira, Ph.D., J.D....

PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announced that it has sold...